Log in

NASDAQ:CSTLCastle Biosciences Stock Price, Forecast & News

+1.11 (+2.72 %)
(As of 07/9/2020 04:00 PM ET)
Today's Range
Now: $41.99
50-Day Range
MA: $38.43
52-Week Range
Now: $41.99
Volume147,800 shs
Average Volume334,523 shs
Market Capitalization$723.07 million
P/E RatioN/A
Dividend YieldN/A
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:CSTL



Sales & Book Value

Annual Sales$51.87 million
Cash Flow$0.14 per share
Book Value$4.98 per share


Net Income$5.28 million


Market Cap$723.07 million
Next Earnings Date9/1/2020 (Estimated)
OptionableNot Optionable

Receive CSTL News and Ratings via Email

Sign-up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.

Castle Biosciences (NASDAQ:CSTL) Frequently Asked Questions

How has Castle Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Castle Biosciences' stock was trading at $28.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CSTL shares have increased by 44.9% and is now trading at $41.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Castle Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Castle Biosciences.

When is Castle Biosciences' next earnings date?

Castle Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, September 1st 2020. View our earnings forecast for Castle Biosciences.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences (NASDAQ:CSTL) released its earnings results on Monday, May, 11th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.18. The firm had revenue of $17.42 million for the quarter, compared to analysts' expectations of $14.40 million. Castle Biosciences had a net margin of 11.90% and a return on equity of 3.88%. View Castle Biosciences' earnings history.

What price target have analysts set for CSTL?

4 brokers have issued 12 month price targets for Castle Biosciences' shares. Their forecasts range from $35.00 to $47.00. On average, they expect Castle Biosciences' share price to reach $42.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Castle Biosciences.

Has Castle Biosciences been receiving favorable news coverage?

News articles about CSTL stock have been trending negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Castle Biosciences earned a news impact score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Castle Biosciences.

Are investors shorting Castle Biosciences?

Castle Biosciences saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,290,000 shares, an increase of 13.2% from the May 31st total of 1,140,000 shares. Based on an average daily trading volume, of 183,600 shares, the days-to-cover ratio is presently 7.0 days. Approximately 13.3% of the company's shares are short sold. View Castle Biosciences' Current Options Chain.

Who are some of Castle Biosciences' key competitors?

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), DexCom (DXCM), Trade Desk (TTD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Beyond Meat (BYND), Clovis Oncology (CLVS), Coupa Software (COUP), Dicerna Pharmaceuticals (DRNA) and Incyte (INCY).

Who are Castle Biosciences' key executives?

Castle Biosciences' management team includes the following people:
  • Mr. Derek J. Maetzold, Founder, CEO, Pres & Director (Age 57)
  • Mr. Frank Stokes, Chief Financial Officer (Age 49)
  • Mr. Bernhard E. Spiess, Chief Operating Officer (Age 59)
  • Mr. Toby W. Juvenal, Sr. VP of Sales (Age 59)
  • Ms. Kristen Oelschlager R.N., RN, Sr. VP of Clinical Operations (Age 51)

When did Castle Biosciences IPO?

(CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Castle Biosciences' stock symbol?

Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."

How do I buy shares of Castle Biosciences?

Shares of CSTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Castle Biosciences' stock price today?

One share of CSTL stock can currently be purchased for approximately $41.99.

How big of a company is Castle Biosciences?

Castle Biosciences has a market capitalization of $723.07 million and generates $51.87 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.81) on an earnings per share basis. Castle Biosciences employs 94 workers across the globe.

What is Castle Biosciences' official website?

The official website for Castle Biosciences is castlebiosciences.com.

How can I contact Castle Biosciences?

Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company can be reached via phone at 866-788-9007 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.